Excaliard's anti-scarring candidate positive in Phase II
This article was originally published in Scrip
Executive Summary
Excaliard Pharmaceuticals' anti-scarring candidate EXC 001 significantly reduces scar severity in patients undergoing elective abdominoplasty surgery ("tummy tuck") compared with placebo, top-line 12-week Phase II data suggest.